DSIP — Research Dossier
Evidence grading
Structure
Nonapeptide (9 aa)
First isolated from rabbit cerebral venous blood (1970s)
First isolated
1974–1977
Schoenenberger and Monnier; cerebral venous blood of sleeping rabbits
Defined receptor
None established
No agreed receptor or signalling pathway identified after 50 years
FDA approval
None
No major regulator approval; research-use-only in the UK
DSIP has one of the thinnest and least consistent evidence bases of any compound in this library — and this dossier says so plainly rather than dressing a 50-year-old curiosity as a validated sleep aid.
DSIP (delta sleep-inducing peptide) is a naturally occurring nonapeptide first isolated in the 1970s by Schoenenberger and Monnier from the cerebral venous blood of rabbits during induced slow-wave (delta) sleep. It was named for the observation that transferring this blood factor appeared to promote delta-wave sleep in recipients. Despite five decades of intermittent study, its biology remains poorly resolved.
Of the compounds in this library, DSIP carries the most important honesty caveat: it has no established receptor, no agreed mechanism, and an evidence base that has been persistently difficult to replicate. Researchers looking for sleep-modulating peptides should read the evidence base section before relying on any DSIP marketing claim.
“DSIP has no established receptor and no agreed mechanism — and its defining observation, that transferring cerebral venous blood from sleeping rabbits induced delta-wave sleep in recipients, has been inconsistently reproduced in controlled conditions over five decades of study.”
— Schoenenberger and Monnier (1977); subsequent reproducibility reviews
Mechanism — the honest answer: unknown
DSIP has no established receptor and no agreed mechanism. This is the central honesty point. Reported effects have spanned sleep modulation, stress and cortisol modulation, and various endocrine influences, but the molecule does not map to a defined signalling pathway the way GHRH analogues or melanocortin agonists do.
Its classification as a sleep-inducing factor has itself been questioned: the original transfer-experiment paradigm is methodologically difficult to control, and the sleep-inducing effect is not a consistent finding across laboratories or species.
Evidence base
Sparse and inconsistent. The early literature reported endocrine and sleep-related effects in animal and small human studies, but findings have been variable and hard to replicate across independent groups. Rigorous modern controlled human trials are essentially absent.
There is no robust, reproducible demonstration of a clinically meaningful sleep effect from exogenous DSIP at this time. Reviews of the DSIP literature (Graf and Kastin) have noted the reproducibility limitations and the absence of a defined receptor or mechanism. DSIP is best understood as a historically interesting candidate whose 50-year inability to generate a replicable mechanism reflects genuine biological uncertainty rather than a gap in research effort.
Regulatory status
Not approved by the FDA, MHRA, or EMA for any indication. Material supplied for laboratory work is research-use-only. Evidence grade: preclinical — and weak even by that standard. DSIP is a historically interesting neuropeptide whose mechanism is undefined and whose effects are inconsistently reproduced. Researchers should treat claims about reliable sleep induction as unsupported by current high-quality evidence.
See also
References
- 1
Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram-(sleep)-inducing peptide Proc Natl Acad Sci USA 1977.
- 2
Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review Neurosci Biobehav Rev 1984.
Research & Laboratory Use Only
This dossier is compiled for research planning and educational purposes only. It summarises published scientific literature and does not constitute medical advice, dosing guidance, or a therapeutic claim. All Nexyra Lab products are for research purposes only and are not for human or veterinary use. Nothing in this document should be interpreted as recommending, endorsing, or facilitating the self-administration of any compound.
A one-time legal review of this template and disclaimer is recommended before the Journal section is made publicly accessible, given the health-adjacent nature of this content.
